Table 3.
Relative potency estimates and 95% confidence intervals based upon Finney’s (1964) bioassay using logarithmic doses.
| Outcome Measure | Morphine relative to Oxycodone |
Confidence intervals |
Assumptions violated |
Morphine relative to Hydrocodone |
Confidence intervals |
Assumptions violated |
|---|---|---|---|---|---|---|
| Physiological | ||||||
| Pupil Diameter * | - | - | 2, 3 | - | - | 2 |
| Oxygen Saturation* | - | - | 3 | - | - | 3 |
| Expired CO2 | - | - | 2, 3 | 0.975 | 0.793-1.188 | |
| Subject-rated | ||||||
| Visual analogs | ||||||
| High | 1.111 | 0.874-1.493 | - | - | 3 | |
| Drug effect | 1.054 | 0.828-1.377 | - | - | 3 | |
| Like | 1.020 | 0.634-1.699 | - | - | 3 | |
| Good effect | 1.051 | 0.785-1.458 | - | - | 3 | |
| Bad effect | - | - | 3, 4 | - | - | 2, 4 |
| Difficulty concentrating | - | - | 3 | - | - | 4 |
| ARCI | ||||||
| PCAG | - | - | 3, 4 | - | - | 4 |
| AMPH | 0.919 | 0.455-1.494 | 0.752 | 0.055-1.222 | ||
| MBG | 1.018 | 0.661-1.613 | 0.862 | 0.352-1.367 | ||
| Agonist Scale | 1.263 | 0.936-2.175 | 0.895 | 0.402-1.455 | ||
| Street value | 1.168 | 0.971-1.472 | 0.928 | 0.666-1.228 | ||
| Ocular tasks | ||||||
| Maddox wing | - | - | 3 | - | - | 3 |
| Flicker/fusion * (#1) | - | - | 4 | - | - | 1, 3, 4 |
| Flicker/fusion * (#2) | 0.667 | 0.017-1.053 | - | - | 3, 4 | |
| Observer-rated adjectives | - | - | 2, 3 | 1.116 | 0.880-1.496 |
All outcome measures, for which significant effects of dose condition were observed in the peak maximum/nadir (denoted by *) were assayed. If an assay was invalid, the assumptions violated are noted by number below (1=Linearity, 2=Parallelism, 3=Preparation, 4=Regression). Morphine is the reference drug. Relative potency is expressed as mg morphine necessary to produce the same effect as 1mg of oxycodone or hydrocodone.